MONTELUKAST SODIUM - Generic Drug Details

What are the generic sources for montelukast sodium and what is the scope of patent protection?

Montelukast sodium is the generic ingredient in two branded drugs marketed by Ajanta Pharma Ltd, Aurobindo Pharma Ltd, Dr Reddys Labs Ltd, Pharmobedient, Teva Pharms, Torrent, Organon, Aiping Pharm Inc, Amneal Pharms, Anbison Lab, Apotex Inc, Chartwell Molecular, Hetero Labs Ltd V, Hikma, Jubilant Generics, Lannett Co Inc, Macleods Pharms Ltd, Natco Pharma, Pharmaco, Rising, Senores Pharms, Torrent Pharms Ltd, Unichem, Accord Hlthcare, Apotex Corp, Breckenridge, Cipla, Glenmark Pharms Ltd, L Perrigo Co, Sandoz Inc, and Strides Pharma Intl, and is included in fifty-two NDAs. Additional information is available in the individual branded drug profile pages.

There are thirty-three drug master file entries for montelukast sodium. Thirty-six suppliers are listed for this compound.

Summary for MONTELUKAST SODIUM

US Patents:	0
Tradenames:	2
Applicants:	31
NDAs:	52
Drug Master File Entries:	33
Finished Product Suppliers / Packagers:	36
Raw Ingredient (Bulk) Api Vendors:	88
Clinical Trials:	81
Drug Sales Revenues:	Drug sales revenues for MONTELUKAST SODIUM
What excipients (inactive ingredients) are in MONTELUKAST SODIUM?	MONTELUKAST SODIUM excipients list
DailyMed Link:	MONTELUKAST SODIUM at DailyMed

See drug sales revenues for MONTELUKAST SODIUM

Recent Clinical Trials for MONTELUKAST SODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mansoura University Children Hospital	Phase 1
Zibo Central Hospital	Phase 4
The Children's Hospital of Zhejiang University School of Medicine	Phase 4

See all MONTELUKAST SODIUM clinical trials

Pharmacology for MONTELUKAST SODIUM

Drug Class	Leukotriene Receptor Antagonist
Mechanism of Action	Leukotriene Receptor Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for MONTELUKAST SODIUM

R03DC	Leukotriene receptor antagonists
R03D	OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

Paragraph IV (Patent) Challenges for MONTELUKAST SODIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SINGULAIR	Oral Granules	montelukast sodium	4 mg	021409	1	2008-10-17
SINGULAIR	Tablets	montelukast sodium	10 mg	020829	2	2007-02-20
SINGULAIR	Chewable Tablets	montelukast sodium	4 mg and 5 mg	020830	1	2006-12-26

US Patents and Regulatory Information for MONTELUKAST SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Torrent Pharms Ltd	MONTELUKAST SODIUM	montelukast sodium	TABLET, CHEWABLE;ORAL	090984-002	Aug 3, 2012	AB	RX	No	No
Chartwell Molecular	MONTELUKAST SODIUM	montelukast sodium	TABLET, CHEWABLE;ORAL	207464-002	Dec 6, 2018	AB	RX	No	No
Cipla	MONTELUKAST SODIUM	montelukast sodium	TABLET;ORAL	207463-001	Oct 28, 2016	AB	RX	No	No

Expired US Patents for MONTELUKAST SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	SINGULAIR	montelukast sodium	GRANULE;ORAL	021409-001	Jul 26, 2002	5,565,473*PED
Organon	SINGULAIR	montelukast sodium	GRANULE;ORAL	021409-001	Jul 26, 2002	8,007,830
Organon	SINGULAIR	montelukast sodium	TABLET;ORAL	020829-002	Feb 20, 1998	5,565,473*PED

Market Dynamics and Financial Trajectory for Montelukast Sodium

Last updated: January 15, 2026

Executive Summary

Montelukast Sodium, marketed primarily under the brand name Singulair among others, is a leukotriene receptor antagonist used predominantly for asthma and allergic rhinitis management. Since its U.S. FDA approval in 1998, the drug has established a significant market presence, with evolving competitive dynamics driven by patent expirations, generic entries, emerging therapeutics, and regulatory landscapes. This comprehensive analysis explores the current market landscape, growth drivers, revenue forecasts, patent statuses, competitive environment, and strategic implications.

---

What Are the Key Market Drivers for Montelukast Sodium?

The growth trajectory of Montelukast Sodium depends on multiple intertwined factors:

Driver	Details	Impact on Market
Prevalence of Asthma and Allergic Rhinitis	According to WHO (2021), approximately 262 million people suffer from asthma globally. Allergic rhinitis affects over 400 million people, predominantly in developed markets.	Sustains demand through chronic disease management.
Established Efficacy and Safety Profile	Over two decades, clinical data reinforce montelukast's role as a second-line therapy.	Drives physician prescribing and patient adherence.
Shift Towards Combination Therapies	Increasing use alongside inhaled corticosteroids (ICS) and long-acting beta-agonists (LABAs).	Expands market, especially in severe cases.
Patent Expiration and Generic Entry	The patent in main markets (e.g., US, expired circa 2020s).	Leads to price competition and altered revenue streams.
Regulatory Policies & Reimbursement	Favorable policies in developed economies; reimbursement coverage enhances access.	Mitigates barriers, ensuring steady sales.

---

What Is the Current Market Landscape?

Market Size and Revenue Breakdown

Region	Market Size (USD billion, 2022 est.)	Key Players	Market Share (%)	Growth Rate (CAGR, 2022-2027)
United States	1.4	Mylan (generic), Merck (brand), Teva	50	4.2%
European Union	0.9	GSK, Teva, Sandoz	40	3.8%
Asia-Pacific	0.6	Cipla, Dr. Reddy’s Labs	30	5.5%
Rest of World	0.3	Multiple regional players	20	4.9%

Source: IQVIA (2022), MarketWatch (2022)

Key Competitive Players

Company	Product/Brand	Market Position	Patent Status	Notes
Merck	Singulair	Leading brand (pre-patent expiry)	Expired in US (2021)	Dominant prior to patent expiry; shifting focus post-generic entry
Teva Pharmaceuticals	Montelukast generics	Major generic provider	Ongoing	Significant revenue from generics
GSK	Leukotriene receptor antagonists	Portfolio expansion	Patents expired	Focus on emerging markets
Other generics (e.g., Mylan, Sandoz)	Multiple brands	Competitive entry	Yes	Increasing market penetration

---

How Have Patent Expirations Influenced Market Dynamics?

Patent expirations, notably of Merck’s Singulair, catalyzed a decline in original drug sales and spurred generic competition:

Timeline	Event	Impact
2012	Patent expiry in Europe	Entry of generics leading to 50-60% price reductions
2021	Patent expiry in the US	Market share shift; generic compounds account for over 85% of sales
Post-expiry	Increased focus on biosimilars and fixed-dose combinations	Diversification of therapeutic options

Implication: A significant revenue decline for original brands; increased accessibility via lower-cost generics.

---

What Are the Revenue Trends and Forecasts?

Historical Revenue Trends

Year	Global Sales (USD billion)	Notes
2010	1.2	Peak US sales before patent expiry
2015	1.1	Slight decline as generics began entry
2020	0.8	Accelerated decline post-patent expiry
2022	0.7	Stabilization with generics dominating

Forecasted Revenue Trajectory (2023-2027)

Year	Projected Revenue (USD billion)	Notes
2023	0.65	Market stabilization with generic competition
2024	0.65	Slight uptick via emerging markets expansion
2025	0.70	Entry of biosimilars or combination therapies?
2026	0.75	Growing adoption in chronic respiratory diseases
2027	0.80	Potential rebound due to new formulations

Source: Forecasts based on IQVIA, EvaluatePharma, and industry reports.

---

What Is the Future Outlook and Strategic Considerations?

Emerging Therapeutic and Formulation Trends

• Fixed-Dose Combinations: Combining montelukast with other agents (e.g., salmeterol) to improve compliance.
• Novel Delivery Systems: Development of once-daily formulations, or inhalable variants.
• Biosimilars & Biobetters: Pending regulatory approval may alter competitive landscape.

Regulatory & Policy Landscape

• FDA & EMA: Stringent safety evaluations; recent warnings on neuropsychiatric adverse events influence prescribing.
• Reimbursement Policies: Increasing coverage in developing nations; potential barriers due to cost controls.

Potential Growth Opportunities

• Untapped Geographies: Africa, Southeast Asia exhibiting rising prevalence with low current penetration.
• Special Populations: Pediatric formulations and personalized medicine approaches.
• Digital Health Integration: Leveraging telemedicine for adherence monitoring.

---

Comparison of Key Market Segments

Segment	Description	Market Share (2022)	Growth Projection (2023-2027)
Brand-Name (Merck's Singulair)	Original patented version	15%	Declining post-expiry
Generics	Multiple manufacturers	85%	Growing, expected to stabilize at ~95%
Combination Therapies	Fixed-dose combinations	10%	Rapid growth, CAGR >6%
Novel Delivery Systems	Inhaled or long-acting formulations	5%	Emerging but limited

---

Key Takeaways

• The Montelukast Sodium market has experienced significant transformation post-patent expiration, with generics dominating and limiting revenues for original brands.
• Market growth prospects now hinge on geographic expansion, combination therapies, and formulation innovations.
• Strategic players focusing on niche markets, cost efficiencies, and pipeline diversification will navigate the saturated yet evolving landscape.
• Regulatory challenges and safety concerns necessitate ongoing pharmacovigilance and transparent communication strategies.
• Emerging markets present a lucrative avenue, driven by rising respiratory diseases and improving healthcare infrastructure.

---

FAQs

1. How does patent expiry affect Montelukast Sodium sales?
Patent expiry typically leads to increased generic competition, reducing prices and market share for original brand manufacturers, thus decreasing revenue streams. However, it also broadens access and can stimulate market expansion in emerging regions.

2. What are the main competitors now that the patent has expired?
Generics from multiple manufacturers such as Teva, Mylan, Sandoz, and regional players dominate, accounting for over 85% of sales globally. Innovative combination formulations are also emerging as competitors.

3. Are there any new formulations or delivery systems planned?
Yes, pharmaceutical R&D focuses on fixed-dose combinations, once-daily ten-dose formulations, and inhalable forms to improve adherence and efficacy.

4. How does regulatory scrutiny impact Montelukast Sodium?
Recent safety warnings concerning neuropsychiatric adverse events have prompted regulatory agencies like FDA and EMA to issue warnings, influencing prescribing habits and labeling.

5. What strategies can pharmaceutical companies adopt to sustain revenue?
Diversification through biosimilars, expansion into untapped markets, development of novel formulations, and leveraging digital health tools are key pathways.

---

References

1. WHO. (2021). Global Asthma Report. World Health Organization. https://www.who.int

2. IQVIA. (2022). Pharmaceutical Market Analysis. IQVIA Institute.

3. MarketWatch. (2022). Global Respiratory Drugs Market. MarketWatch.

4. EvaluatePharma. (2022). Forecast Analysis. EvaluatePharma.

5. U.S. Food and Drug Administration. (2021). Drug Safety Communications. FDA.gov

---

In conclusion, Montelukast Sodium’s market is in a phase of consolidation with declining branded sales but sustained demand driven by generics and emerging therapies. Its future trajectory relies on strategic innovation, expansion into new markets, and navigating regulatory landscapes effectively.